RESUMEN
Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson's disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists in combination with the "caffeine-like effects" of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Ki < 55 nM). Compound 4 (ST-2001, Ki (A1R) = 11.5 nM, Ki (A2AR) = 7.25 nM) and 12 (ST-1992, Ki (A1R) = 11.2 nM, Ki (A2AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg-1, i.p. rats). Compound 12 (2 mg kg-1, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.
Asunto(s)
Antagonistas del Receptor de Adenosina A1/uso terapéutico , Antagonistas del Receptor de Adenosina A2/uso terapéutico , Antagonistas de los Receptores Histamínicos H3/uso terapéutico , Enfermedad de Parkinson Secundaria/tratamiento farmacológico , Antagonistas del Receptor de Adenosina A1/síntesis química , Antagonistas del Receptor de Adenosina A1/metabolismo , Antagonistas del Receptor de Adenosina A2/síntesis química , Antagonistas del Receptor de Adenosina A2/metabolismo , Animales , Discinesias/tratamiento farmacológico , Antagonistas de los Receptores Histamínicos H3/síntesis química , Antagonistas de los Receptores Histamínicos H3/metabolismo , Humanos , Levodopa/farmacología , Masculino , Ratones Endogámicos C57BL , Simulación del Acoplamiento Molecular , Oxidopamina , Enfermedad de Parkinson Secundaria/inducido químicamente , Piperidinas/síntesis química , Piperidinas/metabolismo , Piperidinas/uso terapéutico , Pirimidinas/síntesis química , Pirimidinas/metabolismo , Pirimidinas/uso terapéutico , Pirrolidinas/síntesis química , Pirrolidinas/metabolismo , Pirrolidinas/uso terapéutico , Ratas Sprague-Dawley , Receptor de Adenosina A2A/metabolismo , Receptores Histamínicos H3/metabolismo , Vigilia/efectos de los fármacosRESUMEN
Autism spectrum disorder (ASD) is a complex heterogeneous neurodevelopmental disorder characterized by social and communicative impairments, as well as repetitive and restricted behaviors (RRBs). With the limited effectiveness of current pharmacotherapies in treating repetitive behaviors, the present study determined the effects of acute systemic treatment of the novel multi-targeting ligand ST-2223, with incorporated histamine H3 receptor (H3R) and dopamine D2/D3 receptor affinity properties, on ASD-related RRBs in a male Black and Tan BRachyury (BTBR) mouse model of ASD. ST-2223 (2.5, 5, and 10 mg/kg, i.p.) significantly mitigated the increase in marble burying and self-grooming, and improved reduced spontaneous alternation in BTBR mice (all p < 0.05). Similarly, reference drugs memantine (MEM, 5 mg/kg, i.p.) and aripiprazole (ARP, 1 mg/kg, i.p.), reversed abnormally high levels of several RRBs in BTBR (p < 0.05). Moreover, ST-2223 palliated the disturbed anxiety levels observed in an open field test (all p < 0.05), but did not restore the hyperactivity parameters, whereas MEM failed to restore mouse anxiety and hyperactivity. In addition, ST-2223 (5 mg/kg, i.p.) mitigated oxidative stress status by decreasing the elevated levels of malondialdehyde (MDA), and increasing the levels of decreased glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) in different brain parts of treated BTBR mice (all p < 0.05). These preliminary in vivo findings demonstrate the ameliorative effects of ST-2223 on RRBs in a mouse model of ASD, suggesting its pharmacological prospective to rescue core ASD-related behaviors. Further confirmatory investigations on its effects on various brain neurotransmitters, e.g., dopamine and histamine, in different brain regions are still warranted to corroborate and expand these initial data.
Asunto(s)
Trastorno del Espectro Autista/tratamiento farmacológico , Encéfalo/metabolismo , Antagonistas de los Receptores de Dopamina D2/administración & dosificación , Aseo Animal/efectos de los fármacos , Antagonistas de los Receptores Histamínicos H3/administración & dosificación , Estrés Oxidativo/efectos de los fármacos , Receptores de Dopamina D3/antagonistas & inhibidores , Animales , Ansiedad/tratamiento farmacológico , Encéfalo/efectos de los fármacos , Modelos Animales de Enfermedad , Antagonistas de los Receptores de Dopamina D2/metabolismo , Células HEK293 , Antagonistas de los Receptores Histamínicos H3/metabolismo , Humanos , Ligandos , Locomoción/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D3/metabolismo , Receptores Histamínicos H3/metabolismoRESUMEN
The sphingosine 1-phosphate (S1P) receptor 1 (S1P1) has emerged as a therapeutic target for the treatment of multiple sclerosis (MS). Fingolimod (FTY720) is the first functional antagonist of S1P1 that has been approved for oral treatment of MS. Previously, we have developed novel butterfly derivatives of FTY720 that acted similar to FTY720 in reducing disease symptoms in a mouse model of experimental autoimmune encephalomyelitis (EAE). In this study, we have synthesized a piperidine derivative of the oxazolo-oxazole compounds, denoted ST-1505, and its ring-opened analogue ST-1478, and characterised their in-vitro and in-vivo functions. Notably, the 3-piperidinopropyloxy moiety resembles a structural motif of pitolisant, a drug with histamine H3R antagonistic/inverse agonist activity approved for the treatment of narcolepsy. Both novel compounds exerted H3R affinities, and in addition, ST-1505 was characterised as a dual S1P1+3 agonist, whereas ST-1478 was a dual S1P1+5 agonist. Both multitargeting compounds were also active in mice and reduced the lymphocyte numbers as well as diminished disease symptoms in the mouse model of MS. The effect of ST-1478 was dependent on SK-2 activity suggesting that it is a prodrug like FTY720, but with a more selective S1P receptor activation profile, whereas ST-1505 is a fully active drug even in the absence of SK-2. In summary, these data suggest that the well soluble piperidine derivatives ST-1505 and ST-1478 hold promise as novel drugs for the treatment of MS and other autoimmune or inflammatory diseases, and by their H3R antagonist potency, they might additionally improve cognitive impairment during disease.
Asunto(s)
Encefalomielitis Autoinmune Experimental/prevención & control , Clorhidrato de Fingolimod/administración & dosificación , Antagonistas de los Receptores Histamínicos H3/administración & dosificación , Esclerosis Múltiple/prevención & control , Fármacos Neuroprotectores/administración & dosificación , Receptores de Esfingosina-1-Fosfato/agonistas , Animales , Células CHO , Cricetinae , Cricetulus , Encefalomielitis Autoinmune Experimental/metabolismo , Femenino , Clorhidrato de Fingolimod/análogos & derivados , Clorhidrato de Fingolimod/química , Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Esclerosis Múltiple/metabolismo , Fármacos Neuroprotectores/química , Estructura Secundaria de Proteína , Receptores de Esfingosina-1-Fosfato/metabolismoRESUMEN
INTRODUCTION: Biotransformation constitutes an important aspect of the drug discovery process, to mimic human metabolism of active principal ingredient but also to generate new chemical entities. Several microorganisms such as fungi are well adapted to transform drug, whether at the stage of screening or for large-scale production. OBJECTIVES: Due to the high chemical complexity of the biotransformation media, it seems attractive to develop new analytical strategies in order to guarantee an adequate monitoring and optimize the production of targeted metabolites or drug candidates. METHODS: The model designed for this purpose concerns the biotransformation of a potential histamine H3 antagonist (S38093) in order to produce phase I metabolites. MS, NMR and chemometrics tools were used to monitor biotransformation reactions. RESULTS: First, a screening of eleven filamentous fungi was carried out by UHPLC-UV-MS and principal component analysis to select the best candidates. Subsequently, MS (tR, m/z) and NMR (1H, JRES) fingerprints associated with Consensus OPLS-DA multiblock approach were used to better understand the bioreaction mechanisms in terms of nutrient consumption and hydroxylated metabolites production. Then an experimental design was set up to optimize the production conditions (pH, kinetic) of these target metabolites. CONCLUSION: This study demonstrates how NMR and MS acquisitions combined with chemometric methods offer an innovative analytical strategy to have a grasp of functionalization mechanisms, and identify metabolites and other compounds (amino acids, nutrients, etc.) in complex biotransformation mixtures.
Asunto(s)
Hongos/metabolismo , Antagonistas de los Receptores Histamínicos H3/metabolismo , Metabolómica , Biotransformación , Hongos/efectos de los fármacos , Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/farmacología , Humanos , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Estructura Molecular , Análisis de Componente PrincipalRESUMEN
Growing evidence recommends incorporating the concept of drug-target residence times within drug development and screening programs. For many targets, systematic research for binding kinetics is emerging and reported, as in case of the histamine H3 receptor. Alternatively, fluorescent methods based on Foerster resonance energy transfer have been reported recently but application of fluorescence polarization to kinetics of unlabeled ligands is not known to us. Thus, we established a radiolabel-free, real-time resolving method that is compatible to high-throughput-screening programs with the objective to explore the underlying binding kinetics. This method takes benefit of bodilisant as H3 receptor ligand. Thereby, we detected short residence times around 5â¯min for the H3 receptor ligands ciproxifan, clobenpropit, thioperamide as well as pitolisant. Monitoring association rates, remarkably slower association rate constants were examined for ciproxifan and thioperamide when compared to those of pitolisant or clobenpropit. The affinities for the ligands derived by the kinetic approach differ from affinity estimates in literature using radiolabeled agonists in displacement assays. Further investigation raised exceptional pharmacological properties, consistent with occurrence of secondary binding sites at the H3 receptor. Validation of resulting affinity constants was successfully performed by displacement assays based on fluorescence polarization with bodilisant.
Asunto(s)
Polarización de Fluorescencia/métodos , Agonistas de los Receptores Histamínicos/metabolismo , Antagonistas de los Receptores Histamínicos H3/metabolismo , Receptores Histamínicos H3/metabolismo , Relación Dosis-Respuesta a Droga , Células HEK293 , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos H3/farmacología , Humanos , Ligandos , Unión Proteica/efectos de los fármacos , Unión Proteica/fisiologíaRESUMEN
BACKGROUND: Clobenpropit, a potent antagonist/inverse agonist at the histamine H3 receptor (H3R), reduced the cytotoxic action of 6-hydroxydopamine (6-OHDA) in neuroblastoma SH-SY5Y cells transfected with the human H3R. We therefore set out to study whether this effect involved a receptor-independent action on dopamine transport. METHODS: The uptake of [3H]-dopamine was assayed in SH-SY5Y cells and rat striatal or cerebro-cortical isolated nerve terminals (synaptosomes). Clobenpropit binding to the human norepinephrine (NET) and dopamine (DAT) transporters was analyzed by molecular modeling. RESULTS: In SH-SY5Y cells, [3H]-dopamine uptake was inhibited by desipramine (selective NET inhibitor), GBR-12909 (selective DAT inhibitor), and fluoxetine (selective inhibitor of the serotonin transporter, SERT) with IC50 values 37, 537, and 2800nM, respectively. The potency rank order indicates that [3H]-dopamine uptake is primarily performed by NET. Clobenpropit inhibited [3H]-dopamine uptake (maximum inhibition 82.7±2.8%, IC50 490nM), and the effect was reproduced by the H3R antagonist/inverse agonist iodophenpropit, but not by the agonists R-α-methylhistamine and immepip or the antagonists/inverse agonists ciproxifan and A-331440. Clobenpropit also inhibited [3H]-dopamine uptake by rat striatal and cerebro-cortical synaptosomes (-54.6±11.3% and -46.3±9.6%, respectively, at 10µM). Modeling of the human NET and DAT obtained by homology from the crystal of Drosophila melanogaster DAT showed that clobenpropit can bind to a site also recognized in both transporters by nisoxetine, a potent NET inhibitor. CONCLUSION: These data indicate a direct inhibitory effect of clobenpropit on catecholamine transport.
Asunto(s)
Encéfalo/efectos de los fármacos , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/antagonistas & inhibidores , Inhibidores de Captación de Dopamina/farmacología , Dopamina/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacología , Imidazoles/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Sinaptosomas/efectos de los fármacos , Tiourea/análogos & derivados , Animales , Sitios de Unión , Encéfalo/metabolismo , Línea Celular Tumoral , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/química , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Inhibidores de Captación de Dopamina/química , Inhibidores de Captación de Dopamina/metabolismo , Relación Dosis-Respuesta a Droga , Proteínas de Drosophila/antagonistas & inhibidores , Proteínas de Drosophila/metabolismo , Agonismo Inverso de Drogas , Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/metabolismo , Humanos , Imidazoles/química , Imidazoles/metabolismo , Simulación del Acoplamiento Molecular , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/antagonistas & inhibidores , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/metabolismo , Unión Proteica , Conformación Proteica , Ratas , Receptores Histamínicos H3/metabolismo , Sinaptosomas/metabolismo , Tiourea/química , Tiourea/metabolismo , Tiourea/farmacologíaRESUMEN
A partial agonist and a full antagonist of the histamine H3 receptor have been suggested to have therapeutic effects on cognitive deficits in psychiatric disorders. We have previously shown that neonatal habenula lesion (NHL) induces behavioral deficits that resemble the symptoms of attention deficit/hyperactivity disorder (ADHD). In this study, we examined the effects of three H3 antagonists on ADHD-like behavioral changes caused by NHL in rats. Behavioral tests and administration of the H3 receptor antagonists were performed in juvenile rats with NHL. H3 antagonist administration to juvenile rats dose dependently improved NHL-induced hyperlocomotion, impulsive behavior, and attention deficit. These results suggest that histamine H3 antagonists may be used as alternative therapeutic drugs for the treatment of ADHD.
Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Antagonistas de los Receptores Histamínicos H3/farmacología , Antagonistas de los Receptores Histamínicos H3/uso terapéutico , Animales , Animales Recién Nacidos/lesiones , Trastornos del Conocimiento/tratamiento farmacológico , Modelos Animales de Enfermedad , Habénula/lesiones , Antagonistas de los Receptores Histamínicos H3/metabolismo , Conducta Impulsiva/efectos de los fármacos , Masculino , Memoria/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores Histamínicos H3/metabolismo , Receptores Histamínicos H3/fisiologíaRESUMEN
As a continuation of our search for novel histamine H3 receptor ligands a series of twenty new tert-amyl phenoxyalkylamine derivatives (2-21) was synthesized. Compounds of four to eight carbon atoms spacer alkyl chain were evaluated on their binding properties at human histamine H3 receptor (hH3R). The highest affinities were observed for pentyl derivatives 6-8 (Ki=8.8-23.4nM range) and among them piperidine derivative 6 with Ki=8.8nM. Structures 6, 7 were also classified as antagonists in cAMP accumulation assay (with EC50=157 and 164nM, respectively). Moreover, new compounds were also evaluated for anticonvulsant activity in Antiepileptic Screening Program (ASP) at National Institute of Neurological Disorders and Stroke (USA). Seven compounds (2-4, 9, 11, 12 and 20) showed anticonvulsant activity at maximal electroshock (MES) test in the dose of 30mg/kg at 0.5h. In the subcutaneous pentetrazole (scMET) test compound 4 showed protection at 100 and 300mg/kg dose at mice, however compounds showed high neurotoxicity in rotarod test at used doses. Also, molecular modeling studies were undertaken, to explain affinity of compounds at hH3R (taking into the consideration X-ray analysis of compound 18). In order to estimate "drug-likeness" of selected compounds in silico and experimental evaluation of lipophilicity, metabolic stability and cytotoxicity was performed.
Asunto(s)
Anticonvulsivantes/síntesis química , Antagonistas de los Receptores Histamínicos H3/síntesis química , Piperidinas/química , Receptores Histamínicos H3/química , Animales , Anticonvulsivantes/metabolismo , Anticonvulsivantes/toxicidad , Sitios de Unión , Línea Celular , Proliferación Celular/efectos de los fármacos , Electrochoque , Células HEK293 , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/toxicidad , Humanos , Masculino , Ratones , Simulación del Acoplamiento Molecular , Neuronas/efectos de los fármacos , Piperidinas/metabolismo , Piperidinas/toxicidad , Unión Proteica , Estructura Terciaria de Proteína , Ratas , Ratas Sprague-Dawley , Receptores Histamínicos H3/metabolismo , SolubilidadRESUMEN
Histaminergic H3 inverse agonists, by stimulating central histamine release, represent attractive drug candidates to treat cognitive disorders. The present studies aimed to describe the mechanistic profile of S 38093 a novel H3 receptors inverse agonist. S 38093 displays a moderate affinity for rat, mouse and human H3 receptors (Ki=8.8, 1.44 and 1.2µM, respectively) with no affinity for other histaminergic receptors. In cellular models, the compound was able to antagonize mice H3 receptors (KB=0.65µM) and to suppress cAMP decrease induced by an H3 agonist via human H3 receptors (KB=0.11µM). The antagonism properties of the compound were confirmed by electrophysiological studies on rat hippocampal slices (from 0.1µM). In cells expressing a high H3 density, S 38093 behaved as a moderate inverse agonist at rat and human H3 receptors (EC50=9 and 1.7µM, respectively). S 38093 was rapidly absorbed in mouse and rat (Tmax=0.25-0.5h), slowly in monkey (2h), with a bioavailability ranging from 20% to 60% and t1/2 ranging from 1.5 to 7.4h. The compound was widely distributed with a moderate volume of distribution and low protein binding. The brain distribution of S 38093 was rapid and high. In mice, S 38093 significantly increased ex vivo N-tele-Methylhistamine cerebral levels from 3mg/kg p.o. and antagonized R-α-Methylhistamine-induced dipsogenia from 10mg/kg i.p. Taken together, these data suggest that S 38093, a novel H3 inverse agonist, is a good candidate for further in vivo evaluations, in particular in animal models of cognition.
Asunto(s)
Compuestos de Azabiciclo/farmacología , Benzamidas/farmacología , Agonismo Inverso de Drogas , Agonistas de los Receptores Histamínicos/farmacocinética , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Receptores Histamínicos H3/metabolismo , Animales , Ácido Araquidónico/metabolismo , AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Histamina/metabolismo , Agonistas de los Receptores Histamínicos/metabolismo , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacología , Humanos , Masculino , Ratones , RatasRESUMEN
Effects of the histamine H1 receptor (H1R) antagonists (antihistamines), promethazine (PMZ), orphenadrine (ORP), chlorpheniramine (CLP), pyrilamine (PYR), diphenhydramine (DPH), citerizine (CTZ), and triprolidine (TRP) on the functional properties of the cloned α7 subunit of the human nicotinic acetylcholine receptor expressed in Xenopus oocytes were investigated. Antihistamines inhibited the α7-nicotinic acetylcholine receptor in the order PYR>CLP>TRP>PMZ>ORP≥DPH≥CTZ. Among the antihistamines, PYR showed the highest reversible inhibition of acetylcholine (100 µM)-induced responses with IC50 of 6.2 µM. PYR-induced inhibition was independent of the membrane potential and could not be reversed by increasing the concentration of acetylcholine. Specific binding of [¹²5I] α-bungarotoxin, a selective antagonist for α7-nicotinic acetylcholine receptor, was not changed in the presence of PYR suggesting a non-competitive inhibition of nicotinic receptors. In line with functional experiments, docking studies indicated that PYR can potentially bind allosterically with the α7 transmembrane domain. Our results indicate that the H2-H4 receptor antagonists tested in this study (10 µM) showed negligible inhibition of α7-nicotinic acetylcholine receptors. On the other hand, H1 receptor antagonists inhibited the function of human α7-nicotinic acetylcholine receptor, with varying potencies. These results emphasize the importance of α7-nicotinic acetylcholine receptor for future pharmacological/toxicological profiling.
Asunto(s)
Antagonistas de los Receptores Histamínicos H1/farmacología , Modelos Moleculares , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Pirilamina/farmacología , Receptor Nicotínico de Acetilcolina alfa 7/antagonistas & inhibidores , Regulación Alostérica , Animales , Sitios de Unión , Células Cultivadas , Antagonistas de los Receptores Histamínicos H1/química , Antagonistas de los Receptores Histamínicos H1/metabolismo , Antagonistas de los Receptores H2 de la Histamina/química , Antagonistas de los Receptores H2 de la Histamina/metabolismo , Antagonistas de los Receptores H2 de la Histamina/farmacología , Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacología , Humanos , Ketamina/química , Ketamina/metabolismo , Ketamina/farmacología , Cinética , Conformación Molecular , Simulación del Acoplamiento Molecular , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Oocitos/citología , Oocitos/efectos de los fármacos , Oocitos/metabolismo , Estructura Terciaria de Proteína , Pirilamina/química , Pirilamina/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Xenopus laevis , Receptor Nicotínico de Acetilcolina alfa 7/genética , Receptor Nicotínico de Acetilcolina alfa 7/metabolismoRESUMEN
Combination of AChE inhibiting and histamine H3 receptor antagonizing properties in a single molecule might show synergistic effects to improve cognitive deficits in Alzheimer's disease, since both pharmacological actions are able to enhance cholinergic neurotransmission in the cortex. However, whereas AChE inhibitors prevent hydrolysis of acetylcholine also peripherally, histamine H3 antagonists will raise acetylcholine levels mostly in the brain due to predominant occurrence of the receptor in the central nervous system. In this work, we designed and synthesized two novel classes of tri- and tetracyclic nitrogen-bridgehead compounds acting as dual AChE inhibitors and histamine H3 antagonists by combining the nitrogen-bridgehead moiety of novel AChE inhibitors with a second N-basic fragment based on the piperidinylpropoxy pharmacophore with different spacer lengths. Intensive structure-activity relationships (SARs) with regard to both biological targets led to compound 41 which showed balanced affinities as hAChE inhibitor with IC50 = 33.9 nM, and hH3R antagonism with Ki = 76.2 nM with greater than 200-fold selectivity over the other histamine receptor subtypes. Molecular docking studies were performed to explain the potent AChE inhibition of the target compounds and molecular dynamics studies to explain high affinity at the hH3R.
Asunto(s)
Inhibidores de la Colinesterasa/química , Antagonistas de los Receptores Histamínicos H3/química , Compuestos de Nitrógeno/química , Acetilcolinesterasa/metabolismo , Sitios de Unión/efectos de los fármacos , Sitios de Unión/genética , Inhibidores de la Colinesterasa/síntesis química , Inhibidores de la Colinesterasa/metabolismo , Inhibidores de la Colinesterasa/farmacología , GTP Fosfohidrolasas/metabolismo , Antagonistas de los Receptores Histamínicos H3/síntesis química , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacología , Humanos , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Estructura Molecular , Compuestos de Nitrógeno/síntesis química , Compuestos de Nitrógeno/farmacocinética , Ensayo de Unión Radioligante , Receptores Histamínicos/genética , Receptores Histamínicos/metabolismo , Receptores Histamínicos H1/genética , Receptores Histamínicos H1/metabolismo , Receptores Histamínicos H2/genética , Receptores Histamínicos H2/metabolismo , Receptores Histamínicos H3/genética , Receptores Histamínicos H3/metabolismoRESUMEN
A novel series of non-imidazole bicyclic and tricyclic histamine H3 receptor antagonists has been discovered. Compound 17 was identified as a centrally penetrant molecule with high receptor occupancy which demonstrates robust oral activity in rodent models of obesity. In addition compound 17 possesses clean CYP and hERG profiles and shows no behavioral changes in the Irwin test.
Asunto(s)
Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/uso terapéutico , Obesidad/tratamiento farmacológico , Animales , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Humanos , Microsomas Hepáticos/metabolismo , Ratas , Receptores Histamínicos H3/metabolismoRESUMEN
A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R) antagonists. The SAR was explored and the data obtained set up the starting point and foundation for further optimization. The most potent tool compounds, as exemplified by compounds 2l, 5b, 5d, and 5e, displayed antagonism potencies in the subnanomolar range in in vitro human-H3R FLIPR assays and rhesus monkey H3R binding assays.
Asunto(s)
Amidas/química , Antagonistas de los Receptores Histamínicos H3/química , Receptores Histamínicos H3/química , Urea/química , Amidas/metabolismo , Amidas/uso terapéutico , Animales , Evaluación Preclínica de Medicamentos , Células HEK293 , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/uso terapéutico , Humanos , Macaca mulatta , Obesidad/tratamiento farmacológico , Unión Proteica , Ratas , Receptores Histamínicos H3/genética , Receptores Histamínicos H3/metabolismo , Relación Estructura-Actividad , Urea/metabolismo , Urea/uso terapéuticoRESUMEN
A novel series of histamine H3 receptor (H3R) antagonists was derived from an arylurea lead series (1) via bioisosteric replacement of the urea functionality by an amide linkage. The arylamide series was optimized through SAR studies by a broad variation of substituents in the left-hand side benzoyl residue (analogs 2a-2ag) or replacement of the benzoyl moiety by heteroarylcarbonyl residues (analogs 5a-5n). Compounds 2p and 2q were identified within the series as potent and selective H3R antagonists/inverse agonists with acceptable overall profile. Compound 2q was orally active in food intake inhibition in diet-induced obese (DIO) mice. Compound 2q represents a novel H3R antagonist template with improved in vitro potency and oral efficacy and has its merits as a new lead for further optimization.
Asunto(s)
Amidas/química , Benzamidas/química , Antagonistas de los Receptores Histamínicos H3/química , Pirrolidinas/química , Receptores Histamínicos H3/química , Urea/química , Administración Oral , Amidas/metabolismo , Amidas/uso terapéutico , Animales , Benzamidas/metabolismo , Benzamidas/uso terapéutico , Células CACO-2 , Evaluación Preclínica de Medicamentos , Agonismo Inverso de Drogas , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/uso terapéutico , Humanos , Ratones , Microsomas/metabolismo , Obesidad/tratamiento farmacológico , Unión Proteica , Pirrolidinas/metabolismo , Pirrolidinas/uso terapéutico , Ratas , Receptores Histamínicos H3/genética , Receptores Histamínicos H3/metabolismo , Relación Estructura-Actividad , Urea/metabolismo , Urea/uso terapéuticoRESUMEN
Histamine H(3) receptor antagonists have been widely reported to improve performance in preclinical models of cognition, but more recently efficacy in pain models has also been described. Here, A-960656 ((R)-2-(2-(3-(piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazol-6-yl)pyridazin-3(2H)-one) was profiled as a new structural chemotype. A-960656 was potent in vitro in histamine H(3) receptor binding assays (rat K(i)=76 nM, human K(i)=21 nM), and exhibited functional antagonism in blocking agonist-induced [(35)S]GTPγS binding (rat H(3) K(b)=107 nM, human H(3) K(b)=22 nM), and was highly specific for H(3) receptors in broad screens for non-H(3) sites. In a spinal nerve ligation model of neuropathic pain in rat, oral doses of 1 and 3mg/kg were effective 60 min post dosing with an ED(50) of 2.17 mg/kg and a blood EC(50) of 639 ng/ml. In a model of osteoarthritis pain, oral doses of 0.1, 0.3, and 1mg/kg were effective 1h post dosing with an ED(50) of 0.52 mg/kg and a blood EC(50) of 233 ng/ml. The antinociceptive effect of A-960656 in both pain models was maintained after sub-chronic dosing up to 12 days. A-960656 had excellent rat pharmacokinetics (t(1/2)=1.9h, 84% oral bioavailability) with rapid and efficient brain penetration, and was well tolerated in CNS behavioral safety screens. In summary, A-960656 has properties well suited to probe the pharmacology of histamine H(3) receptors in pain. Its potency and efficacy in animal pain models provide support to the notion that histamine H(3) receptor antagonists are effective in attenuating nociceptive processes.
Asunto(s)
Benzotiazoles/farmacología , Antagonistas de los Receptores Histamínicos H3/farmacología , Neuralgia/tratamiento farmacológico , Osteoartritis/tratamiento farmacológico , Piridazinas/farmacología , Receptores Histamínicos H3/metabolismo , Animales , Benzotiazoles/efectos adversos , Benzotiazoles/metabolismo , Benzotiazoles/farmacocinética , Permeabilidad de la Membrana Celular , Inhibidores Enzimáticos del Citocromo P-450 , Modelos Animales de Enfermedad , Perros , Canales de Potasio Éter-A-Go-Go/antagonistas & inhibidores , Células HEK293 , Corazón/efectos de los fármacos , Antagonistas de los Receptores Histamínicos H3/efectos adversos , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Humanos , Masculino , Osteoartritis de la Rodilla/tratamiento farmacológico , Piridazinas/efectos adversos , Piridazinas/metabolismo , Piridazinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Especificidad por SustratoRESUMEN
The degree of binding of a drug to plasma proteins has a significant effect on its distribution, elimination, and pharmacological effect since only the unbound fraction is available for distribution into extra-vascular space. The binding of DL76 (1-[3-(4-tert-butyl-phenoxy)propyl]piperidine) to bovine serum albumin (BSA) was studied in viitro by equilibrium dialysis at 37 degrees C and pH 7.4 over the concentration range of 0.32-317.18 microM and at a physiological protein concentration of 602 microM. Drug concentrations were determined by validated LC/MS/MS method. Nonlinear regression analyses of the data pointed to a single class of binding sites (m = 1) with a dissociation constant of DL76 equal 49.20 microM. Scatchard plot concave-down curve might indicate positive cooperativity, which was confirmed by the Hill plot with the slope higher than one.
Asunto(s)
Antagonistas de los Receptores Histamínicos H3/metabolismo , Piperidinas/metabolismo , Albúmina Sérica Bovina/metabolismo , Unión ProteicaRESUMEN
Histamine H(3) receptor antagonists enhance cognition in preclinical models and have been proposed as novel therapeutics for cognitive disorders, in particular Alzheimer's disease (AD). Increased neurotransmitter (e.g. acetylcholine and histamine) release associated with this pharmacology may lead to activation of postsynaptic signaling pathways relevant to cognition and neuroprotection, such as increased phosphorylation of CREB, a transcription factor germane to cognitive function, and the inhibitory residue (Ser-9) of GSK3ß, a primary tau kinase associated with AD pathology. In the present studies, acute administration of the H(3)-antagonist ABT-239 (0.01-1.0mg/kg i.p.) increased cortical CREB and S(9)-GSK3ß phosphorylation in CD1 mice. Donepezil, while increasing CREB phosphorylation, did not increase pS(9)-GSK3ß expression in contrast to ABT-239. Continuous (2-wk) s.c. infusion of ABT-239 (0.7 mg/kg/day) normalized reduced cortical CREB and hippocampal S(9)-GSK3ß phosphorylation observed in Tg2576 (APP) AD-transgenic mice. In addition, ABT-239 infusion reversed tau hyperphosphorylation in the spinal cord and hippocampus of TAPP (tau × APP) AD-transgenic mice. Interestingly, ABT-239 produced signaling changes (pS(9)-GSK3ß) in α7 nicotinic acetylcholine receptor (nAChR) knockout mice. In contrast to wild type, these mice do not exhibit α7 nAChR agonist induced phosphorylation, thus suggesting that H(3)-antagonist-mediated signaling is not dependent on ACh-stimulated α7 nAChR activation. In summary, results of these studies suggest that ABT-239 leads to biochemical signaling that promotes cognitive performance as well as attenuation of tau hyperphosphorylation, raising the intriguing possibility that H(3) antagonists have potential for both symptomatic and disease modifying benefit in the treatment of AD.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Benzofuranos/metabolismo , Membrana Celular/metabolismo , Antagonistas de los Receptores Histamínicos H3/metabolismo , Pirrolidinas/metabolismo , Receptores Histamínicos H3/metabolismo , Transducción de Señal/fisiología , Enfermedad de Alzheimer/tratamiento farmacológico , Animales , Benzofuranos/farmacología , Benzofuranos/uso terapéutico , Proteína de Unión a CREB/metabolismo , Membrana Celular/efectos de los fármacos , Femenino , Glucógeno Sintasa Quinasa 3/metabolismo , Glucógeno Sintasa Quinasa 3 beta , Antagonistas de los Receptores Histamínicos H3/farmacología , Antagonistas de los Receptores Histamínicos H3/uso terapéutico , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Pirrolidinas/farmacología , Pirrolidinas/uso terapéutico , Transducción de Señal/efectos de los fármacos , Resultado del TratamientoRESUMEN
H(3) antagonists increase the release of brain histamine, acetylcholine, noradrenaline, and dopamine, neurotransmitters that are known to modulate cognitive processes. The ability to release brain histamine supports the effect on attention and vigilance, but histamine also modulates other cognitive domains such as short-term and long-term memory. A number of H(3) antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1R,3R)-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clinical area for the potential treatment of human cognitive disorders. H(3) antagonists exhibited wake-promoting effects in humans and efficacy in narcoleptic patients, indicating target engagement, but some of them were not efficacious in patients suffering from attention-deficit hyperactivity disorder and schizophrenic patients. Preclinical studies have also shown that H(3) antagonists activate intracellular signaling pathways that may improve cognitive efficacy and disease-modifying effects in Alzheimer's disease. Ongoing clinical studies will be able to determine the utility of H(3) antagonists for the treatment of cognitive disorders in humans.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Trastornos del Conocimiento/tratamiento farmacológico , Descubrimiento de Drogas , Antagonistas de los Receptores Histamínicos H3/uso terapéutico , Receptores Histamínicos H3 , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/psicología , Animales , Trastornos del Conocimiento/metabolismo , Trastornos del Conocimiento/psicología , Descubrimiento de Drogas/tendencias , Antagonistas de los Receptores Histamínicos H3/metabolismo , Humanos , Receptores Histamínicos H3/metabolismo , Resultado del TratamientoRESUMEN
The histamine H3 receptor (H3R) plays a regulatory role in the presynaptic release of histamine and several other neurotransmitters, and thus, it is an attractive target for central nervous system indications including cognitive disorders, narcolepsy, attention-deficit hyperactivity disorder, and pain. The development of H3R antagonists was complicated by the similarities between the pharmacophores of H3R and human Ether-à-go-go related gene (hERG) channel blockers, a fact that probably prevented promising compounds from being progressed into the clinic. Using a three-dimensional in silico modeling approach complemented with automated and manual patch clamping, we were able to separate these two pharmacophores and to develop highly potent H3R antagonists with reduced risk of hERG liabilities from initial hit series with low selectivity identified in a high-throughput screening campaign.
Asunto(s)
Diseño de Fármacos , Canales de Potasio Éter-A-Go-Go/antagonistas & inhibidores , Ensayos Analíticos de Alto Rendimiento , Antagonistas de los Receptores Histamínicos H3/farmacología , Técnicas de Placa-Clamp , Receptores Histamínicos H3/metabolismo , Animales , Simulación por Computador , Cricetinae , Cricetulus , Descubrimiento de Drogas , Canales de Potasio Éter-A-Go-Go/metabolismo , Antagonistas de los Receptores Histamínicos H3/efectos adversos , Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/metabolismo , Humanos , Modelos Moleculares , Relación Estructura-ActividadRESUMEN
Using a focused screen of biogenic amine compounds we identified a novel series of H(3)R antagonists. A preliminary SAR study led to reduction of MW while increasing binding affinity and potency. Optimization of the physical properties of the series led to (S)-6n, with improved brain to plasma exposure and efficacy in both water intake and novel object recognition models.